SCHEMBL10150553

SCHEMBL10150553

COP1(=S)OC[C@H]2O[C@@H](n3cnc4c(N)ccnc43)C(O)C2O1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ RAPGEF3 O95398 2/20 0.53
▸ RXFP1 Q9HBX9 2/20 0.53
▸ STING1 Q86WV6 8/20 0.52
▸ LMNA P02545 2/20 0.52
▸ GMNN O75496 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ RAPGEF4 Q8WZA2 1/20 0.52
▸ PDE4A P27815 4/20 0.47
▸ PDE4B Q07343 4/20 0.47
▸ PDE4C Q08493 4/20 0.47
▸ PDE4D Q08499 4/20 0.47
▸ PDE3B Q13370 1/20 0.47
▸ PDE3A Q14432 1/20 0.47
▸ ADORA2A P29274 1/20 0.46
▸ ADORA2B P29275 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16158834 0.86 KMT2A (0.51) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL15906324 0.86 KMT2A (0.76) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL1106673 0.86 KMT2A (0.76) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL10239446 0.86 KMT2A (0.76) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL1133093 0.86 KMT2A (0.76) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL10150583 0.86 RXFP1 (0.51) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL10150545 0.85 KMT2A (0.58) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL10150550 0.84 KMT2A (0.55) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL10150526 0.81 STING1 (0.56) KMT2AMEN1ALDH1A1RAPGEF3RXFP1
SCHEMBL10150541 0.80 KMT2A (0.53) KMT2AMEN1ALDH1A1RAPGEF3RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170002037-A1 CYCLIC NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. 2017-01-05 — — US disclosed
US-9365605-B2 Cyclic nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2016-06-14 — — US disclosed
US-20140303108-A1 CYCLIC NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. 2014-10-09 — — US disclosed
US-8772474-B2 Cyclic nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-07-08 — — US disclosed
US-20120165286-A1 CYCLIC NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303108-A1 CYCLIC NUCLEOTIDE ANALOGS NT5C2, NTPCR, PNP KMT2A 3789/4885MEN1 1451/4885ALDH1A1 2755/4885
US-20170002037-A1 CYCLIC NUCLEOTIDE ANALOGS NT5C2, NTPCR, PNP KMT2A 3789/4885MEN1 1451/4885ALDH1A1 2755/4885
US-20120165286-A1 CYCLIC NUCLEOTIDE ANALOGS NT5C2, NTPCR, PNP KMT2A 3789/4885MEN1 1451/4885ALDH1A1 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback